Track topics on Twitter Track topics that are important to you
Published on BioPortfolio: 2017-11-27T05:47:06-0500
About 40 patients with histologically and/or clinically confirmed and/or suspected NET are anticipated to be enrolled during 3 years from initiating the study. Patients will be recruited ...
The goal of this clinical research study is to use 68GA-DOTATOC instead of the standard-of-care 111-In-pentetreotide as a tracer chemical during PET/CT scans for diagnosing neuroendocrine ...
Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater n...
This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors.
This pilot clinical trial studies gallium Ga 68-edotreotide (68Ga-DOTATOC) positron emission tomography (PET)/computed tomography (CT) in finding brain tumors in younger patients. Diagnost...
Pharmaceutical grade DOTATOC kits compliant with all the quality control criteria were formulated and radiolabeled withGa in high yields. Comparison with module-basedGa-DOTATOC established product equ...
PET imaging with 68Ga-labeled tracers has seen a dramatic increase over the past five years primarily due to the increased accessibility of 68Ge/68Ga generators, the availability of tracers with super...
68Ga-PSMA-11 is currently the most popular prostate-specific membrane antigen (PSMA) radioligand used in the clinic to detect prostate cancer and metastases. However, the high uptake of 68Ga-PSMA-11 i...
Peptide receptor radionuclide therapy is an effective, well-tolerated, treatment for well-differentiated neuroendocrine tumors, resulting in a significant survival benefit and improvement of quality o...
Both NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) and DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) derivatives have been used as bifunctional chelating agents (BFCAs) for the...
The fraction of a blood sample, following CENTRIFUGATION, that is distinguished as a thin light-colored layer between the RED BLOOD CELLS, underneath it, and the PLASMA, above it. It is composed mostly of WHITE BLOOD CELLS and PLATELETS.
The number of RED BLOOD CELLS per unit volume in a sample of venous BLOOD.
The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.
Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.
The taking of a blood sample to determine its character as a whole, to identify levels of its component cells, chemicals, gases, or other constituents, to perform pathological examination, etc.